182 related articles for article (PubMed ID: 36382885)
1. A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I.
Kayigwe AN; M Darby J; Lyons AB; L Patchett A; Lisowski L; Liu GS; S Flies A
J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36382885
[TBL] [Abstract][Full Text] [Related]
2. Inducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells.
Ong CEB; Lyons AB; Woods GM; Flies AS
Front Immunol; 2018; 9():3117. PubMed ID: 30692995
[TBL] [Abstract][Full Text] [Related]
3. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Flies AS; Lyons AB; Woods GM
Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624
[TBL] [Abstract][Full Text] [Related]
4. Devil Facial Tumours: Towards a Vaccine.
Owen RS; Siddle HV
Immunol Invest; 2019 Oct; 48(7):719-736. PubMed ID: 31161832
[TBL] [Abstract][Full Text] [Related]
5. Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Coorens THH; Darby J; Wilson R; McKay MJ; Kamath KS; Rubin A; Wakefield M; Mcintosh L; Mangiola S; Pye RJ; Flies AS; Corcoran LM; Lyons AB; Woods GM; Murchison EP; Papenfuss AT; Tovar C
Cell Mol Life Sci; 2020 May; 77(9):1847-1858. PubMed ID: 31375869
[TBL] [Abstract][Full Text] [Related]
6. The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer.
Caldwell A; Coleby R; Tovar C; Stammnitz MR; Kwon YM; Owen RS; Tringides M; Murchison EP; Skjødt K; Thomas GJ; Kaufman J; Elliott T; Woods GM; Siddle HV
Elife; 2018 Aug; 7():. PubMed ID: 30103855
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal plasticity of devil facial tumour cells during in vivo vaccine and immunotherapy trials.
Patchett AL; Tovar C; Blackburn NB; Woods GM; Lyons AB
Immunol Cell Biol; 2021 Aug; 99(7):711-723. PubMed ID: 33667023
[TBL] [Abstract][Full Text] [Related]
8. Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.
Ong CEB; Cheng Y; Siddle HV; Lyons AB; Woods GM; Flies AS
Open Biol; 2022 Oct; 12(10):220208. PubMed ID: 36259237
[TBL] [Abstract][Full Text] [Related]
9. Automated Analysis of PD1 and PDL1 Expression in Lymph Nodes and the Microenvironment of Transmissible Tumors in Tasmanian Devils.
Russell GG; Palmieri C; Darby J; Morris GP; Fountain-Jones NM; Pye RJ; Flies AS
Immunol Invest; 2023 Nov; 52(6):661-680. PubMed ID: 37267050
[TBL] [Abstract][Full Text] [Related]
10. The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.
Gastaldello A; Ramarathinam SH; Bailey A; Owen R; Turner S; Kontouli N; Elliott T; Skipp P; Purcell AW; Siddle HV
Immunology; 2021 Jun; 163(2):169-184. PubMed ID: 33460454
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicle proteomes of two transmissible cancers of Tasmanian devils reveal tenascin-C as a serum-based differential diagnostic biomarker.
Espejo C; Wilson R; Willms E; Ruiz-Aravena M; Pye RJ; Jones ME; Hill AF; Woods GM; Lyons AB
Cell Mol Life Sci; 2021 Dec; 78(23):7537-7555. PubMed ID: 34655299
[TBL] [Abstract][Full Text] [Related]
13. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
Tovar C; Pye RJ; Kreiss A; Cheng Y; Brown GK; Darby J; Malley RC; Siddle HV; Skjødt K; Kaufman J; Silva A; Baz Morelli A; Papenfuss AT; Corcoran LM; Murphy JM; Pearse MJ; Belov K; Lyons AB; Woods GM
Sci Rep; 2017 Mar; 7():43827. PubMed ID: 28276463
[TBL] [Abstract][Full Text] [Related]
14. An oral bait vaccination approach for the Tasmanian devil facial tumor diseases.
Flies AS; Flies EJ; Fox S; Gilbert A; Johnson SR; Liu GS; Lyons AB; Patchett AL; Pemberton D; Pye RJ
Expert Rev Vaccines; 2020 Jan; 19(1):1-10. PubMed ID: 31971036
[No Abstract] [Full Text] [Related]
15. PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Flies AS; Lyons AB; Corcoran LM; Papenfuss AT; Murphy JM; Knowles GW; Woods GM; Hayball JD
Front Immunol; 2016; 7():581. PubMed ID: 28018348
[TBL] [Abstract][Full Text] [Related]
16. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).
Hayes DA; Kunde DA; Taylor RL; Pyecroft SB; Sohal SS; Snow ET
PLoS One; 2017; 12(6):e0177919. PubMed ID: 28591206
[TBL] [Abstract][Full Text] [Related]
17. The role of MHC genes in contagious cancer: the story of Tasmanian devils.
Caldwell A; Siddle HV
Immunogenetics; 2017 Aug; 69(8-9):537-545. PubMed ID: 28695294
[TBL] [Abstract][Full Text] [Related]
18. A second transmissible cancer in Tasmanian devils.
Pye RJ; Pemberton D; Tovar C; Tubio JM; Dun KA; Fox S; Darby J; Hayes D; Knowles GW; Kreiss A; Siddle HV; Swift K; Lyons AB; Murchison EP; Woods GM
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):374-9. PubMed ID: 26711993
[TBL] [Abstract][Full Text] [Related]
19. Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.
Pye R; Patchett A; McLennan E; Thomson R; Carver S; Fox S; Pemberton D; Kreiss A; Baz Morelli A; Silva A; Pearse MJ; Corcoran LM; Belov K; Hogg CJ; Woods GM; Lyons AB
Front Immunol; 2018; 9():259. PubMed ID: 29515577
[TBL] [Abstract][Full Text] [Related]
20. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.
Kreiss A; Brown GK; Tovar C; Lyons AB; Woods GM
Vaccine; 2015 Jun; 33(26):3016-25. PubMed ID: 25708088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]